Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex Pharmaceuticals's book value per share for the quarter that ended in Mar. 2026 was MXN1,373.71.
During the past 12 months, Vertex Pharmaceuticals's average Book Value Per Share Growth Rate was 18.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 36.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vertex Pharmaceuticals was 97.50% per year. The lowest was -58.90% per year. And the median was 15.10% per year.
During the past 13 years, the highest P/B Ratio of Vertex Pharmaceuticals was 25.85. The lowest was 4.81. And the median was 7.24.
Vertex Pharmaceuticals (MEX:VRTX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Vertex Pharmaceuticals Book Value per Share Related Terms
Vertex Pharmaceuticals Book Value per Share Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, ALNY, RVMD: Book Value per Share Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of MXN1,373.71 mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Book Value per Share of MXN1,373.71 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Book Value per Share too high?
Vertex Pharmaceuticals' current Book Value per Share is MXN1,373.71. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Book Value per Share compare to REGN and ALNY?
Vertex Pharmaceuticals' Book Value per Share of MXN1,373.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Book Value per Share is MXN1,373.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,914.24, compared to a current price of MXN8,474.00 — trading 4.9% below its estimated fair value. The current Book Value per Share is MXN1,373.71. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Book Value per Share is MXN1,373.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,474.00 is trading 4.9% below its estimated GF Value™ of MXN8,914.24.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Book Value per Share: MXN1,373.71
GF Value™: MXN8,914.24 vs. price of MXN8,474.00 (4.9% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
